Education
About Us
Working with TipRanks
Follow Us
Evommune, Inc. (EVMN)
NYSE:EVMN
EVMN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $16.70 and its highest was $24.03 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $554.51M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Evommune, Inc. released its earnings results on Dec 11, 2025. The company reported -$8.07 earnings per share for the quarter, missing the consensus estimate of -$6.081 by -$1.989.
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 31,524,094 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Evommune, Inc. reported an EPS of -$8.07 in its last earnings report, missing expectations of -$6.081. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Company Description
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$39.33
▲(123.59% Upside)
Ownership Overview
49.18% Insiders
―
Mutual Funds
― Other Institutional Investors
50.35% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---